2015
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics And Clinical Risk Management 2015, Volume 11: 95-105. PMID: 25609974, PMCID: PMC4298300, DOI: 10.2147/tcrm.s32193.Peer-Reviewed Original ResearchPainful diabetic neuropathyDiabetic neuropathyOpioid-based therapyCancer-related painDiabetic neuropathic painChronic pain conditionsGastrointestinal side effectsNorepinephrine reuptake inhibitorsΜ-opioid agonistMechanism of actionNeuropathic painPain conditionsReuptake inhibitorsBack painArthritic painClinical efficacyEffective medicationsClinical studiesSide effectsPainTapentadolNeuropathyOne-thirdMedicationsDiabetes
2014
Chromosomal Aberrations and Exon 1 Mutation in the AKR1B1 Gene in Patients with Diabetic Neuropathy.
Saraswathy R, Anand S, Kunnumpurath SK, Kurian RJ, Kaye AD, Vadivelu N. Chromosomal Aberrations and Exon 1 Mutation in the AKR1B1 Gene in Patients with Diabetic Neuropathy. Ochsner Journal 2014, 14: 339-42. PMID: 25249799, PMCID: PMC4171791.Peer-Reviewed Original ResearchType 2 diabetes mellitusPainful diabetic neuropathyDiabetic neuropathyAKR1B1 geneDiabetes mellitusChromosomal aberrationsNeuropathic pathogenesisTremendous morbidityDM patientsTreatment optionsNeuropathyOxidative DNA damageExon 1 mutationsPatientsControl groupPathophysiological processesCultured lymphocytesPatient samplesChromosomal damagePilot investigationHigh rateSignificant mutationsPossible mutationsDNA damageSignificant number
2013
Patient considerations in the use of tapentadol for moderate to severe pain
Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthcare And Patient Safety 2013, Volume 5: 151-159. PMID: 23861601, PMCID: PMC3704302, DOI: 10.2147/dhps.s28829.Peer-Reviewed Original ResearchTapentadol ERTapentadol IRSevere painChronic painOpioid agonistsClinical trialsSide effectsChronic painful diabetic neuropathyMu-opioid receptor agonistCentral nervous system depressantsSimilar pain reliefTraditional opioid agonistsUncontrolled postoperative painSevere acute painSevere chronic painGastrointestinal adverse effectsPainful diabetic neuropathyCommon side effectsNorepinephrine reuptake inhibitorsPost-surgical patientsOpioid receptor agonistsUse of tapentadolDrug Administration approvalMonoamine oxidase inhibitorsPotent opioid agonistDiabetic neuropathy
Vadivelu N. Diabetic neuropathy. International Journal Of Nutrition Pharmacology Neurological Diseases 2013, 3: 332-334. DOI: 10.4103/2231-0738.119839.Peer-Reviewed Original ResearchDiabetic neuropathyNerve conduction testsPainful diabetic neuropathyLong-term diabetesFoot examsCentral sensitizationNerve damageSerious complicationsTerm diabetesCommon siteNeuropathyConduction testsDiabetesCell damageOxidative stressPainGene therapyTreatmentPlant extractsComplicationsPatientsTherapyDamageSensitization